MAX inactivation deregulates the MYC network and induces neuroendocrine neoplasia in multiple tissues

Area of Science:

• Molecular biology
• Cancer research
• Genetics

Background:

• The MYC transcription factor, along with its partner MAX, regulates gene expression in normal and cancerous cells.
• Inactivating mutations in MAX are linked to neuroendocrine tumors like pheochromocytoma, pituitary adenoma, and small cell lung cancer.
• The precise mechanisms and scope of MAX's tumor suppressor functions remain unclear.

Purpose of the Study:

• To investigate the role of MAX in neuroendocrine tumorigenesis.
• To elucidate the mechanisms by which MAX loss contributes to tumor development.
• To understand how MAX influences the broader MYC network in cancer.

Main Methods:

• Deletion of the Max gene in mouse models across various neuroendocrine tissues.
• Analysis of tumor development in Max-deficient mice, including cooperation with Rb1/Trp53 loss.
• Examination of genomic occupancy shifts of MYC network members in thyroid tumor cell lines with MAX loss.

Main Results:

• Max inactivation alone led to pituitary adenomas in mice.
• Combined Max inactivation with Rb1/Trp53 loss accelerated medullary thyroid C cell and pituitary adenoma development.
• MAX loss caused significant alterations in the genomic binding of MNT, MLX, and MondoA, promoting neoplastic cell functions.

Conclusions:

• MAX functions as a broad suppressor of neuroendocrine tumorigenesis.
• MAX maintains tumor suppression by balancing genomic occupancy within the MYC transcription factor network.
• Understanding MAX's role offers insights into potential therapeutic strategies for neuroendocrine cancers.